Bruce Bode

Oct 9, 2024 | dom-pubs.onlinelibrary.wiley.com | Georgia Davis |Anne Peters |Bruce Bode |Anders Carlson

1 INTRODUCTION Comprehensive management of type 2 diabetes (T2D) requires a multifaceted approach to achieve care goals surrounding blood pressure, lipids and glucose targets to reduce the risks of micro- and macrovascular complications.1 The use of glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) with their associated cardiorenal benefits highlights how advances in glucose-lowering therapy can change the paradigm for pharmacologic...